Table 3.
Distribution of pepsinogens and G-17 mean value among patients stratified for the presence of autoimmune disease
| Patients, n | PGI, ng/mLa | PGII, ng/mLa | PGI:II ratio | G-17, pmol/La | |
| All CAAG patients | 108 | 61.9 (10) | 14.2 (2) | 2.2 (10) | 232.1 (36) |
| gNET comorbidity | |||||
| Yes | 18 | 16.4 (14) | 11.0 (4) | 1.6 (2) | 217.3 (167) |
| No | 90 | 67.9 (114) | 14.8 (23) | 4.5 (5) | 246(414) |
| P = 0.06 | P = 0.018 | ||||
| Any autoimmune disease | 74 | 60.8 (129) | 15.2 (25) | 4.3 (5) | 239 (429) |
| Autoimmune thyroiditis | 64 | 60.0 (96) | 15.8 (27) | 4.2 (4) | 262 (460) |
| Diabetes | 31 | 60.1 (87) | 11.3 (6.9) | 4.9 (6) | 192.5 (264) |
| Vitiligo | 6 | 21.5 (24) | 9.4 (3.8) | 3.3 (5) | 349.5 (290) |
| Psoriasis | 3 | 10.2 (10.5) | 8.8 (1) | 1.26 (1) | 645.5 (447) |
| Autoimmune polyendocrine syndrome | 14 | 64.2 (80) | 11.2 (7) | 5.3 (6) | 227 (310) |
Statistical analysis: Fisher exact test.
CAAG, chronic atrophic autoimmune gastritis; G-17; gastrin-17; gNET, gastric neuroendocrine tumor; PGI, pepsinogen I; PGII, pepsinogen II.
a
Mean (SD).